Sequence: CRGDKGPDC
| Experiment Id | EXP000731 |
|---|---|
| Paper | Endosomolytic and Tumor-Penetrating Mesoporous Silica Nanoparticles for siRNA/miRNA Combination Canc |
| Peptide | iRGD |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | |
| Rna Concentration | In vivo dosing: 1 mg/kg siPlk1 + 1 mg/kg miR-200c (i.v.); ICG 720 µg/kg; twice weekly for 3 weeks |
| Mixing Ratio | siRNA:miRNA=1:1 (w/w); MSN:RNAs=30:1 (w/w); lipids:MSN=2:1 (w/w); fixed ICG:RNA = 1 µg/mL : 200 nM (per RNA) |
| Formulation Format | iRGD-modified lipid-coated mesoporous silica nanoparticle (iMSN) with ICG photosensitizer |
| Formulation Components | NH2-MSN core (100–200 nm, 4 nm pores) adsorbing siRNA+miRNA; ICG loaded; lipid coat SPC/DSPE-mPEG/DSPE-PEG-DBCO (2:2:1 w/w/w); iRGD (azido) click-conjugated (DSPE-PEG-DBCO:iRGD 1:1 molar) |
| Size Nm | 100.00 |
| Zeta Mv | -19.00 |
| Model Scope | in_vivo |
| Model Type | in vivo (mouse orthotopic metastatic breast cancer) |
| Cell Lines Or Primary Cells | |
| Animal Model | Immunocompromised female NCG mice with orthotopic MDA-MB-231.Luc tumors (mammary fat pad); metastasis monitored by IVIS |
| Administration Route | Intravenous (tail vein) + 808 nm laser irradiation of primary tumor (5 min, ~4 h post-dose; some groups −light) |
| Output Type | in vivo therapeutic efficacy |
| Output Value | Significant primary tumor growth suppression/regression and marked reduction of metastasis for iMSN/siPlk1+miR-200c+ICG with light |
| Output Units | |
| Output Notes | Biodistribution: sustained tumor accumulation of ICG signal and tumor section fluorescence (FAM-siRNA/ICG) vs controls; IHC showed downregulation of Plk1 and ZEB1 in tumors in treated group; lung metastasis markedly reduced with +light. |
| Toxicity Notes | No significant weight loss; blood counts/biochemistry indicated no toxic effects (reported). |
| Curation Notes |